One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Aytu BioScience logo
Aytu BioScience AYTU
$ 2.66 0.0%
report update icon

Quarterly report 2027-Q1
added 11-16-2026

Aytu BioScience Balance Sheet 2026-2005 | AYTU

Brief balance sheet overview of Aytu BioScience

The comparison uses five available annual reports from the 2019–2023 interval.

Assets rose from $34.7 million to $136.5 million, a gain of +293%, while CAGR was about 40.8%. The balance sheet expanded rapidly.

Liability growth of +251.4% trailed asset growth of +293%. The funding structure became more resilient.

Equity finances 28.8% of the balance sheet, compared with 20.4% at the start. The cushion remains adequate.

Net debt moved below zero to -$7 million, reflecting surplus cash over debt.

Cash represents 16.8% of assets versus 31.8% initially, showing how the immediate liquidity reserve changed.

The balance sheet includes a negative accumulated result of -$304.1 million. It should be assessed alongside historical profits and capital distributions.

Overall assessment

Aytu BioScience has a solid balance sheet cushion. Capital and liquidity support development without excessive reliance on debt.

Annual Balance Sheet Aytu BioScience

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005

Net Debt

-17 M -19.9 M -8.42 M -7.01 M -3.13 M -48.5 M -45.6 M -11 M -7.01 M -802 K -8.05 M -7.35 M -2.64 M 97.6 K 67.9 K 48.3 K - - - - - -

Long Term Debt

9.1 M 10.9 M 10.9 M 14.7 M 15 M 180 K - - - - - - - - - - - - - - - -

Long Term Debt Current

221 K 137 K 712 K 1.26 M 1.23 M 940 K 300 K - - - - - - - - - - - - - - -

Total Non Current Liabilities

15.1 M 42.1 M 28.2 M 28.1 M 28.9 M 18.7 M 29.5 M 22.3 M 4.24 M 7.39 M 4.15 M 1.13 M 554 K - - - - - - - - -

Total Current Liabilities

54.7 M 63.1 M 62.2 M 69 M 64.4 M 109 M 28.3 M 5.37 M 3.39 M 3.61 M 10.1 M 1.48 M - 121 K 82.4 K - - - - - - -

Total Liabilities

- - - 97.1 M 93.3 M 128 M 57.8 M 27.6 M 7.64 M 11 M 14.3 M 2.61 M 6.65 M 121 K 82.4 K 58.4 K - - - - - -

Deferred Revenue

- - - - - - 339 K - - - - 85.7 K 85.7 K - - - - - - - - -

Retained Earnings

-348 M -334 M -320 M -304 M -287 M -178 M -120 M -106 M -79.3 M -69.1 M -46.6 M -18.4 M -10.7 M -569 K -500 -500 - - - - - -

Total Assets

105 M 124 M 118 M 136 M 138 M 266 M 153 M 34.7 M 21.1 M 15 M 24.3 M 18.2 M 12 M 9.67 K 12.6 K 22.8 K - - - - - -

Cash and Cash Equivalents

26.3 M 31 M 20 M 23 M 19.4 M 49.6 M 48.1 M 11 M 7.01 M 802 K 8.05 M 7.35 M 2.64 M 1.86 K 109 3.99 K 1.54 K - - - - 100

Book Value

105 M 124 M 118 M 39.4 M 44.3 M 138 M 95 M 7.09 M 13.4 M 4 M 10.1 M 15.6 M 5.37 M -111 K -69.7 K -35.6 K - - - - - -

Total Shareholders Equity

35.3 M 19 M 27.7 M 39.4 M 44.3 M 138 M 95 M 7.09 M 13.4 M 4 M 10.1 M 15.6 M 5.37 M -111 K -69.7 K -35.6 K -55.6 K -13.6 K 26 K 18.8 K 57.9 K 20.4 K

All numbers in USD currency

Quarterly Balance Sheet Aytu BioScience

2027-Q1 2026-Q4 2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

785 K 853 K 9.55 M 10 M 10.4 M 10 M 10.4 M 1.11 M 9.54 M 9.98 M 10.4 M 15 M - 15 M 1.15 M 1.47 M 1.77 M 2.09 M 2.41 M 15 M 2.76 M 2.62 M 2.87 M 211 K 237 K 725 K 804 K 292 K 314 K 23.4 M 5.13 M 5.04 M 5.13 M 5.04 M - 5.04 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

14.3 M 15.1 M 16.6 M 42.2 M 35.8 M 42.2 M 35.8 M 21.4 M 18.6 M 21.4 M 24.8 M 34.2 M 14.4 M 34.2 M 20.9 M 28.1 M 28.4 M 28.9 M 27.3 M - 18.2 M 18.7 M 44.7 M 28.2 M 28.7 M 29.5 M 31.2 M 41.4 M 22.6 M - 17.8 M 17.8 M 4.27 M 4.24 M 6.28 M 11 M 11.4 M 7.39 M 4.04 M 4.09 M 4.28 M 4.15 M 1.21 M 6.35 M - 1.09 M 447 K 2.51 M 6.17 M - 6.61 M 6.49 M - - - - - - - - - - - - -

Total Liabilities

67.6 M 69.7 M - - - - - - - - - - - - 106 M 95.6 M 102 M 93.3 M 108 M 93.3 M 116 M 128 M 128 M 54 M 50.2 M 58.3 M 73.2 M 57.4 M 28.7 M 57.4 M 22.3 M 22.5 M 7.85 M 7.64 M 10.6 M 15.8 M 14.9 M 11 M 7.4 M 11.1 M 13 M 14.3 M 4.42 M 9.15 M 14.3 M 2.57 M 9.65 M 2.57 M 7.95 M - 6.66 M 6.65 M - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - 100 K 100 K 400 K 100 K 400 K 200 K 200 K 200 K 476 K 233 K 339 K 233 K 339 K 339 K - - 14 K - 14 K - 14 K - - - - - - 85.7 K 85.7 K 85.7 K 85.7 K 85.7 K 85.7 K 85.7 K - 85.7 K 85.7 K - - - - - - - - - - - - -

Retained Earnings

-352 M -348 M -348 M -342 M -332 M -342 M -332 M -318 M -314 M -318 M -318 M -312 M -315 M -312 M -302 M -294 M -288 M -287 M -271 M -287 M -206 M -178 M -159 M -134 M -124 M -120 M -117 M -112 M -111 M -112 M -91.9 M -87.4 M -82.7 M -79.3 M -79.8 M -77 M -73.3 M -69.1 M -62.3 M -57.1 M -52.3 M -46.6 M -31.3 M -24 M -46.6 M -18.4 M -12.6 M -656 K -20.7 M -646 K -500 -500 -500 -500 -500 -500 -500 -500 -500 -500 -500 -500 -500 -500 -500

Total Assets

99.2 M 105 M 112 M 122 M 125 M 122 M 125 M 116 M 124 M 116 M 116 M 131 M 129 M 131 M 147 M 141 M 150 M 138 M 169 M 138 M 228 M 266 M 272 M 167 M 141 M 153 M 159 M 74.5 M 31 M 74.5 M 38.3 M 42.4 M 18 M 21.1 M 23.4 M 18.9 M 21.2 M 15 M 15.9 M 21.5 M 15 M 24.3 M 22 M 24.4 M 20.2 M 18.2 M 10.2 M 7.98 K 21.4 M 11.2 K 13.5 K 5.63 K 7.16 K 7.16 K 9.67 K 9.67 K 9.67 K 11.9 K 12.6 K 12.6 K 12.6 K 18.8 K 22.8 K 22.8 K 22.8 K

Cash and Cash Equivalents

25.5 M 26.3 M 26.7 M 30 M 32.6 M 30 M 32.6 M 20.4 M 18.2 M 20.4 M 20.1 M 19.5 M 19.8 M 19.5 M 19.2 M 19.5 M 23.8 M 19.4 M 27.6 M 19.4 M 40.6 M 49.9 M 46.8 M 62.3 M 38.2 M 48.3 M 62.3 M 5.26 M 7.01 M 5.26 M 14.6 M 17.8 M 3.96 M 7.1 M 12.1 M 4 M 7.02 M 878 K 3.55 M 5.23 M 2.75 M 8.05 M 8.67 M 11 M 8.05 M 7.35 M 1.49 M 100 10.1 M 161 K 8.97 K 184 445 445 1.86 K 2.91 M 445 701 109 109 701 1.72 K 3.99 K 3.99 K 1.72 K

Book Value

31.6 M 35.3 M 112 M 122 M 125 M - - 116 M - - - 131 M - - 40.9 M 45.8 M 48.3 M 44.3 M 61.1 M 44.3 M 112 M 138 M 143 M 113 M 91.1 M 95 M 85.7 M 17.1 M 2.32 M 17.1 M 16 M 19.9 M 10.1 M 13.4 M 12.8 M 3.03 M 6.35 M 4 M 8.52 M 10.4 M 1.99 M 10.1 M 17.6 M 15.3 M 5.94 M 15.6 M 551 K -2.56 M 13.4 M 11.2 K -6.65 M -6.64 M 7.16 K 7.16 K 9.67 K 9.67 K 9.67 K 11.9 K 12.6 K 12.6 K 12.6 K 18.8 K 22.8 K 22.8 K 22.8 K

Total Shareholders Equity

31.6 M 35.3 M 35.1 M 14.2 M 23.2 M 14.2 M 23.2 M 30.8 M 34.9 M 30.8 M 29.8 M 32.9 M 30.8 M 32.9 M 40.9 M 45.8 M 48.3 M 44.3 M 57.7 M 44.3 M 112 M 138 M 143 M 113 M 91.1 M 95 M 85.7 M 17.1 M 2.32 M 17.1 M 16 M 19.9 M 10.1 M 13.4 M 12.8 M 3.03 M 6.35 M 4 M 8.52 M 10.4 M 7.19 M 10.1 M 17.6 M 15.3 M 10.1 M 15.6 M 551 K -52.9 K 13.4 M -44.1 K -36 K -148 K -126 K -126 K -111 K -111 K -111 K -82.2 K -69.7 K -69.7 K -69.7 K -47.6 K -35.6 K -35.6 K -35.6 K

All numbers in USD currency

Balance Sheet is a fundamental financial report of Aytu BioScience, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 3.11 -8.94 % $ 482 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
- 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
- - $ 35.3 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
- -18.25 % $ 5.04 M israelIsrael
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
- 0.52 % $ 821 M danmarkDanmark
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
- -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
- - $ 69.7 B britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
- - $ 109 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
- -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
- - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
- 31.87 % $ 1.61 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
- 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
- - $ 728 M usaUSA
Regulus Therapeutics Regulus Therapeutics
RGLS
- - $ 155 M usaUSA
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
- - $ 127 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA